中国癌症杂志 ›› 2016, Vol. 26 ›› Issue (12): 1025-1030.doi: 10.19401/j.cnki.1007-3639.2016.12.010

• 论著 • 上一篇    下一篇

PainVision系统量化评估癌痛及化疗神经毒性的应用分析

赵 瑜1,杨 森1,余 怡1,王 辉1,赵 昆1,赵华新2,许 青1,2   

  1. 1. 同济大学附属第十人民医院肿瘤科,上海 200072
    2. 上海市皮肤病医院肿瘤科,上海 200443
  • 出版日期:2016-12-30 发布日期:2017-01-23
  • 通信作者: 许 青 E-mail: xuqingmd@aliyun.com
  • 基金资助:
    上海市卫生系统先进适宜技术推广项目(2013SY046)。

Initial analysis of PainVision system in quantitative assessment of cancer pain and chemotherapyinduced neuropathy

ZHAO Yu1, YANG Sen1, YU Yi1, WANG Hui1, ZHAO Kun1, ZHAO Huaxin2, XU Qing1,2   

  1. 1. Department of Medical Oncology, Tenth People’s Hospital of Tongji University, Shanghai 200072, China; 2. Department of Medical Oncology, Dermatology Hospital of Shanghai, Shanghai 200443, China
  • Published:2016-12-30 Online:2017-01-23
  • Contact: XU Qing E-mail: xuqingmd@aliyun.com

摘要: 背景与目的:癌症相关性疼痛是晚期肿瘤患者的重要临床症状,而化疗常导致周围神经病变,引发疼痛,严重影响患者的生活质量。目前癌痛的评估大都通过患者主观量表来实现,缺乏客观评价手段。本研究借助PainVision系统(PV法)从神经电生理角度定量地进行癌痛评估,检测分析化疗导致的神经病变程度。方法:癌痛患者通过数字疼痛强度量表(numerical rating scale,NRS)主观量表和PV法同时进行疼痛评估,将PV法所得检测值与NRS评分进行相关性分析;对化疗患者进行电流知觉阈值(current perception threshold,CPT)检测,了解化疗对患者CPT水平的影响,尝试PV法进行化疗神经毒性的检测。结果:癌痛患者所测得疼痛比(PainRatio)和患者NRS评分线性相关(Pearson系数为0.849,P<0.001);伴有神经毒性临床症状的患者CPT水平升高,但接受奥沙利铂、紫杉醇和其他药物化疗后的患者CPT水平未见明显差异。结论:PV法可以定量地进行癌痛评估,有助于相对客观地进行癌痛分析。化疗后有明显神经病变的患者出现CPT升高,提示PV法具有潜在检测与评估化疗导致神经毒性的临床应用价值。

关键词: 癌痛评估, PainVision系统, 化疗后神经病变

Abstract: Background and purpose: Cancer-related pain is one of the most important symptoms of patients with advanced cancer. Chemotherapy sometimes induces peripheral neuropathy and pain. These symptoms seriously affect patients’ quality of life. Cancer pain assessment is now achieved by the subjective scales of patients, but lacking objective measurement. In this study, we used the neurotic electrophysiological method by way of PainVision system (PV system) to evaluate cancer pain quantitatively to detect and analyze degree of chemotherapy-induced neuropathy. Methods: We obtained numerical rating scale (NRS) scores from patients receiving analgesics and calculated the PainRatio from PV system at the same time. Then we analyzed the relationship between NRS and PainRatio scores. We detected current perception threshold (CPT) levels of patients receiving chemotherapy to find the correlation between chemotherapy and CPT level, and attempt to evaluate chemotherapy-induced neuropathy. Results: PainRatio scores were linearly associated with NRS scores (Pearson correlation coefficient=0.849, P<0.001). Patients with neuropathy symptoms got higher CPTs. However, no statistically significant difference was observed between patients treated with oxaliplatin, paclitaxel and other agents. Conclusion: PainVision system can be used in cancer pain assessment quantitatively, and be helpful in cancer pain assessment objectively. Patients with defined neuropathy showed higher CPTs, indicating the potential clinical value of PV system in detecting and evaluating chemotherapy-induced neuropathy.

Key words: Cancer pain assessment, PainVision system, Chemotherapy-induced neuropathy